Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-1862-2019

Drug recall · September 25, 2019

Anagrelide Capsules recall

Why: Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.

Lots / codes

Lot #: BFE2E003, Exp 08/31/2020

Quantity
2472 bottles
Company
Torrent Pharma Inc., Basking Ridge, NJ
Distribution
Nationwide in the USA and Puerto Rico
Initiated
September 6, 2019 · Voluntary: Firm initiated
Classified
September 16, 2019
Reported
September 25, 2019
Ended
November 3, 2020
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Anagrelide

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.